Literature DB >> 34043444

Immunotherapy in Older Adults With Cancer.

Carolyn J Presley1, Fabio Gomes2, Christin E Burd3, Ravindran Kanesvaran4, Melisa L Wong5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34043444      PMCID： PMC8260908          DOI： 10.1200/JCO.21.00138

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   50.717


× No keyword cloud information.
  66 in total

1.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Authors:  Achim Rittmeyer; Fabrice Barlesi; Daniel Waterkamp; Keunchil Park; Fortunato Ciardiello; Joachim von Pawel; Shirish M Gadgeel; Toyoaki Hida; Dariusz M Kowalski; Manuel Cobo Dols; Diego L Cortinovis; Joseph Leach; Jonathan Polikoff; Carlos Barrios; Fairooz Kabbinavar; Osvaldo Arén Frontera; Filippo De Marinis; Hande Turna; Jong-Seok Lee; Marcus Ballinger; Marcin Kowanetz; Pei He; Daniel S Chen; Alan Sandler; David R Gandara
Journal:  Lancet       Date:  2016-12-13       Impact factor: 79.321

2.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

3.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

4.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

5.  Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients.

Authors:  Guy Ben-Betzalel; Yael Steinberg-Silman; Ronen Stoff; Nethanel Asher; Ronnie Shapira-Frommer; Jacob Schachter; Gal Markel
Journal:  Eur J Cancer       Date:  2019-01-14       Impact factor: 9.162

Review 6.  HSC Aging and Senescent Immune Remodeling.

Authors:  Michael D Denkinger; Hanna Leins; Reinhold Schirmbeck; Maria Carolina Florian; Hartmut Geiger
Journal:  Trends Immunol       Date:  2015-11-21       Impact factor: 16.687

7.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

8.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

Review 9.  The molecular balancing act of p16(INK4a) in cancer and aging.

Authors:  Kyle M LaPak; Christin E Burd
Journal:  Mol Cancer Res       Date:  2013-10-17       Impact factor: 5.852

10.  Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis.

Authors:  Rawad Elias; Anita Giobbie-Hurder; Nadine Jackson McCleary; Patrick Ott; F Stephen Hodi; Osama Rahma
Journal:  J Immunother Cancer       Date:  2018-04-04       Impact factor: 13.751
View more
  6 in total

1.  Antibody-drug conjugates in treating older patients suffering from cancer: what is the real value?

Authors:  Gianluca Perego; Antonio Ghidini; Andrea Luciani; Fausto Petrelli
Journal:  Hum Vaccin Immunother       Date:  2021-12-02       Impact factor: 3.452

Review 2.  Older Patients with Lung Cancer: a Summary of Seminal Contributions to Optimal Patient Care.

Authors:  Alina Basnet; Asrar Alahmadi; Ajeet Gajra
Journal:  Curr Oncol Rep       Date:  2022-07-28       Impact factor: 5.945

3.  Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study.

Authors:  Umberto Basso; Federico Paolieri; Mimma Rizzo; Ugo De Giorgi; Sergio Bracarda; Lorenzo Antonuzzo; Francesco Atzori; Giacomo Cartenì; Giuseppe Procopio; Lucia Fratino; Manolo D'Arcangelo; Giuseppe Fornarini; Paolo Zucali; Antonio Cusmai; Matteo Santoni; Stefania Pipitone; Claudia Carella; Stefano Panni; Filippo Maria Deppieri; Vittorina Zagonel; Giampaolo Tortora
Journal:  Cancers (Basel)       Date:  2022-05-04       Impact factor: 6.575

4.  A Geriatric Assessment Intervention to Reduce Treatment Toxicity Among Older Adults With Advanced Lung Cancer: A Subgroup Analysis From a Cluster Randomized Controlled Trial.

Authors:  Carolyn J Presley; Mostafa R Mohamed; Eva Culakova; Marie Flannery; Pooja H Vibhakar; Rebecca Hoyd; Arya Amini; Noam VanderWalde; Melisa L Wong; Yukari Tsubata; Daniel J Spakowicz; Supriya G Mohile
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 5.738

5.  First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan.

Authors:  Yasushi Goto; Atsuhisa Tamura; Hirotaka Matsumoto; Kazutoshi Isobe; Tomohiro Ozaki; Melissa L Santorelli; Kazuko Taniguchi; Tetsu Kamitani; Masato Irisawa; Kingo Kanda; Machiko Abe; Thomas Burke; Hiroshi Nokihara
Journal:  JTO Clin Res Rep       Date:  2022-08-05

Review 6.  Ageing and cancer: a research gap to fill.

Authors:  Eric Solary; Nancy Abou-Zeid; Fabien Calvo
Journal:  Mol Oncol       Date:  2022-05-21       Impact factor: 7.449
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.